About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a company based in Conshohocken (United States) founded in 2011 was acquired by Synta Pharmaceuticals in April 2016. Madrigal Pharmaceuticals has raised $38.38 million across 2 funding rounds from investors including Madrigal. The company has 528 employees as of December 31, 2024. Madrigal Pharmaceuticals offers products and services including Rezdiffra. Madrigal Pharmaceuticals operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Akero Therapeutics, among others.
- Headquarter Conshohocken, United States
- Employees 528 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Madrigal Pharmaceuticals, Inc.
-
Annual Revenue
$180.13 M (USD)0as on Dec 31, 2024
-
Net Profit
-$465.89 M (USD)-24.69as on Dec 31, 2024
-
EBITDA
-$496.78 M (USD)-30.74as on Dec 31, 2024
-
Total Equity Funding
$38.38 M (USD)
in 2 rounds
-
Latest Funding Round
$35 M (USD), Series A
Jun 30, 2017
- Investors
-
Employee Count
528
as on Dec 31, 2024
-
Acquired by
Synta Pharmaceuticals
(Apr 14, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol MDGL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals offers a comprehensive portfolio of products and services, including Rezdiffra.
Treats NASH with moderate to advanced liver fibrosis.
People of Madrigal Pharmaceuticals
Unlock access to complete
Area Team
78 people
Leadership Team
68 people
Sales and Marketing
26 people
Operations Team
20 people
Thought Team
13 people
Data Analysis and Operations Team
12 people
Software Development Team
12 people
Product Management Team
11 people
Unlock access to complete
Funding Insights of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals has successfully raised a total of $38.38M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $35 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Madrigal Pharmaceuticals
Madrigal Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Madrigal.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Small molecule drugs are developed for cancer and inflammatory diseases.
|
Locked | Locked | Locked |
Investor details for Madrigal Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Madrigal Pharmaceuticals
Investment portfolio details for Madrigal Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Madrigal Pharmaceuticals
Detailed financials for Madrigal Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Madrigal Pharmaceuticals Comparisons
Peer comparison for Madrigal Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Akero Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for metabolic disorders are developed.
|
Detailed competitors of Madrigal Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Madrigal Pharmaceuticals
Complete news archive for Madrigal Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Madrigal Pharmaceuticals
Madrigal Pharmaceuticals was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Madrigal Pharmaceuticals is headquartered in Conshohocken, United States. It is registered at Conshohocken, Pennsylvania, United States.
Madrigal Pharmaceuticals is a funded company, having raised a total of $38.38M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Madrigal Pharmaceuticals is 528.
Annual revenue of Madrigal Pharmaceuticals is $180.13M as on Dec 31, 2024.
Madrigal Pharmaceuticals was founded in 2011 and is headquartered in Conshohocken, United States. Operations are centered on the development of small molecule therapeutics targeting cardiovascular and metabolic diseases, including non-alcoholic steatohepatitis. The company focuses on advancing drug candidates through clinical stages within the biopharmaceutical sector, with activities spanning research, preclinical testing, and regulatory processes in the United States.
Madrigal Pharmaceuticals's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Akero Therapeutics.
Madrigal Pharmaceuticals offers Rezdiffra.
Yes, Madrigal Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol MDGL.
Madrigal Pharmaceuticals has 1 investor. Key investors include Madrigal.
The ticker symbol of Madrigal Pharmaceuticals is MDGL on NASDAQ.